Top

Published in:

01-03-2008 | Brief Report

Rituximab for refractory focal segmental glomerulosclerosis

Authors: Makiko Nakayama, Koichi Kamei, Kandai Nozu, Kentaro Matsuoka, Atsuko Nakagawa, Mayumi Sako, Kazumoto Iijima

Published in: Pediatric Nephrology | Issue 3/2008

Abstract

We present the cases of two children with steroid-resistant nephrotic syndrome (SRNS) who were treated with rituximab (anti-CD20 monoclonal antibody). Both were resistant to conventional therapy, and renal biopsy showed focal segmental glomerulosclerosis (FSGS). Combination therapy with methylprednisolone pulse therapy and plasmapheresis was the only way to decrease proteinuria. However, the patients suffered severe reactions to steroid treatment. We therefore treated them with rituximab in a single dose of 375 mg/m², which resulted in the rapid clearing of circulating CD19-positive B cells. One month after rituximab treatment, both achieved partial remission; one patient has maintained complete remission for 8 months, and the other relapsed 8 months after the first rituximab treatment with the recovery of peripheral B-cell counts and received a second rituximab treatment. She achieved complete remission 5 months after the second course and has maintained the remission for 2 months. We conclude that rituximab may be an effective treatment for refractory SRNS with FSGS.

Gipson DS, Gibson K, Gipson PE, Watkins S, Moxey-Mims M (2003) Therapeutic approach to FSGS in children. Pediatr Nephrol 22:28–36CrossRef

Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP (1994) Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 330:7–14PubMedCrossRef

Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–883PubMedCrossRef

Salama AD, Pusey CD (2006) Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2:221–230PubMedCrossRef

Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360:923–924PubMedCrossRef

Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797PubMedCrossRef

Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663PubMedCrossRef

Pescoviz MD, Book BK, Sider RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963CrossRef

Gilbert RD, Hulse E, Rigden S (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21:1698–1700PubMedCrossRef

10.

Westphal S, Hansson S, Mjornstedt L, Molne J, Swerkersson S, Friman S (2006) Early recurrence of nephrotic syndrome (immunoglobulin M nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab. Transplant Proc 38:2659–2660PubMedCrossRef

11.

Francois H, Daugas E, Bensman A, Ronco P (2007) Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 49:158–161PubMedCrossRef

12.

Smith GC (2007) Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 22:893–898PubMedCrossRef

13.

Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356:2751–2752PubMedCrossRef

14.

Hariharan S, Peddi VR, Savin VJ, Johnson CP, First MR, Roza AM, Adams MB (1998) Recurrent and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry. Am J Kidney Dis 31:928–931PubMed

15.

Artero ML, Sharma R, Savin VJ, Vincenti F (1994) Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23:574–581PubMed

16.

Sharma M, Sharma R, McCarthy ET, Savin VJ (1999) “The FSGS factor:” enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 10:552–561PubMed

17.

Sharma M, Sharma R, McCarthy ET, Savin VJ (2004) The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med 229:85–98

18.

Porakishvili N, Mageed R, Jamin C, Pers JO, Kulikova N, Renaudineau Y, Lydyard PM, Youinou P (2001) Recent progress in the understanding of B-cell functions in autoimmunity. Scand J Immunol 54:30–38PubMedCrossRef

19.

Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54:2377–2386PubMedCrossRef

20.

Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456–473PubMedCrossRef

Title: Rituximab for refractory focal segmental glomerulosclerosis
Authors: Makiko Nakayama
Koichi Kamei
Kandai Nozu
Kentaro Matsuoka
Atsuko Nakagawa
Mayumi Sako
Kazumoto Iijima
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 3/2008
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-007-0640-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rituximab for refractory focal segmental glomerulosclerosis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Automated peritoneal dialysis as the modality of choice: a single-center, 3-year experience with 458 children in Mexico

Dimercaptosuccinic acid (DMSA) renal scan in the evaluation of hypertension in children

Expression of mRNA for functional molecules in urinary sediment in glomerulonephritis

Arterial thrombosis associated with factor V Leiden and methylenetetrahydrofolate reductase C677T mutation in childhood membranous glomerulonephritis

C1q nephropathy in two young sisters

Recurrent pleural effusion during peritoneal dialysis: answer